AbbVie to buy Landos Biopharma for up to $212M
by 
AbbVie Inc. and Landos Biopharma, Inc. had announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.
“With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn’s disease,” said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie.
“This announcement is a testament to Landos’ talented team and their commitment to our mission of creating oral treatments that can address a therapeutic gap,” said Gregory Oakes, president and chief executive officer, Landos. “NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn’s disease. With AbbVie’s therapeutic area leadership and expertise in global development, they are the right company to further advance NX-13.”
AbbVie’s Rinvoq has already been approved by the U.S. Food and Drug Administration (FDA) to treat ulcerative colitis; the firm is also seeking FDA approval for the condition for Skyrizi, another key drug in its portfolio. In a statement, the firms said that they anticipate the deal to close in the second quarter.
Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/